Sara Pellegrino | executive |
Frederick Vogt | executive |
James Ziegler | executive |
Igor Bilinsky | executive |
Friedrich Graf Finckenstein | executive |
Jean-Marc Bellemin | executive |
Yanan Zhu | analyst |
Tyler Van Buren | analyst |
Peter Lawson | analyst |
Colleen Hanley | analyst |
Dina Elmonshed | analyst |
Joseph Catanzaro | analyst |
Asthika Goonewardene | analyst |
Reni Benjamin | analyst |
Raj Puri | executive |
Andrea Tan | analyst |
Kelsey Goodwin | analyst |
Benjamin Burnett | analyst |
Welcome to the Iovance Biotherapeutics conference call to discuss the full year 2023 results and recent corporate updates. My name is Kevin, and I'll be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.
I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications, Iovance. Sara, you may begin.